Hypertension

After adjustment for known cardiovascular risk factors, investigators found women with a hypertensive disorder of pregnancy, including preeclampsia and gestational hypertension, during their first pregnancy had a 63% greater risk of future cardiovascular disease compared to women with normotensive pregnancies.

There was no statistically significant difference in mean systolic blood pressure for the self-monitoring groups vs the usual care group.

Treating 100 older patients (≥60 years) with hypertension for approximately 3 years would prevent 1 major adverse cardiovascular event.

The rate of long-term survival after 10 years in patients surviving the initial hospital stay after OHCA was between 62% and 64%.

The participants included more than 2,000 pregnant individuals at higher risk of preeclampsia.

The decision to initiate low-dose aspirin use for CVD prevention in adults aged 40 to 59 years with a 10% or greater 10-year CVD risk should be individualized.

Each weight-loss regimen had similar success in obesity management, regardless of patients reducing their calorie consumption through time-restricted eating or through calorie restriction alone.

Patients from the lowest BMI, HbA1c, SBP, and LDL-C population quartile had 3.9, 3.8, 1.9, and 0.9 years of additional life expectancy, respectively.

Individuals in the intervention arm walked a mean of 647 more steps per day compared with the control arm.

Greater adherence to a Mediterranean-style diet was associated with a 22% reduction in odds of developing preeclampsia, with this effect more apparent in Black women, according to a recent study.

The higher time at BP target ranged from 64% in the triple pill group to 43% in the usual care group

Non-exposure to aspirin in patients with hypertension at risk of ASCVD was associated with decreased risk of cardiovascular events.

More research is needed to identify barriers and test interventions to improve hypertension screening and CVD prevention in children with autism

Once a day readings over a year would detect 98.3% of the first Afib >24 hour episodes, while the probability of ≥1 false positive reading would be 98%.

Desai discusses the potential long-term effects of mavacamten and what it could mean for a patient population with HCM.

Results of the CHAP project demonstrate active treatment of chronic mild hypertension was associated with reductions in risk of adverse pregnancy outcomes and is unlikely to harm the developing child.

A pilot study presented at ACC.22 demonstrates the impact of implementation of an RPM program to improve blood pressure control in patients with hypertension at primary care clinics.

Large variations were observed in the transition between monotherapy and dual combination therapy for hypertension across countries and demographic group.

Deep learning analyses of photographic images and other test results in clinical trials may reduce cost and improve the consistency and accuracy of end point assessments.

Patients with tachyarrhythmia or hypertension as their underlying trigger of type 2 MI had a lower mortality than patients with hypotension, hypoxemia, or anemia.

A look into the uptake of semaglutide, what the agent represents, and what is coming further in obesity management.

A randomized trial comparing the effects of immediate testing and disclosure versus delayed testing, results suggest disclosing results of APOL1 testing led to reductions in blood pressure and meaningful lifestyle changes among patients with hypertension.

Findings from REDUCE-IT show icosapent ethyl was projected to be cost-effective compared with standard care in patients with high CV risk despite statin therapy.

A pilot trial suggests telemedicine methods need to be tailored to reach adversely affected populations including Black patients on Medicare or Medicaid.

Data show atherosclerotic burden was heterogeneous across LDL-C levels and risk is shown to be consistently associated with plaque burden.

Data from the PATH-BP study suggests patients receiving daily acetaminophen experienced significant increases in systolic and diastolic blood pressure after just 2 weeks of receiving the medication.

The NDA has been assigned standard review with a PDUFA target action date in late November 2022.

No difference was observed between atrial shunt placement and sham in the endpoint of CVD death, non-fatal ischemic stroke at 12 months, and rate of total heart failure events at 24 months.

Knowing the symptoms and risk factors of CVD unique to women can aid in awareness and prevention efforts.

Dr. Poornima explores improving engagement in women’s cardiovascular care from both a provider and a patient level.